AdventHealth Sebring

Heart failure (HF) and colorectal cancer (CRC) are major public health concerns among the aging population in the United States. This study aimed to investigate temporal, regional, urbanization and racial trends in mortality among adults with HF and CRC aged ≥65years. Mortality data were sourced from the Centers for Disease Control and Prevention Wide-Ranging Online Data for Epidemiologic Research (CDC WONDER) database, utilizing ICD-10 codes to identify deaths related to colon cancer and heart failure from 1999 to 2020. Age-adjusted mortality rates (AAMRs) per 100,000 individuals were calculated, along with Annual Percentage Changes (APCs) and their respective 95% confidence intervals (CIs). The AAMRs remained relatively stable between 1999 (8.5) and 2004 (7.3) (APC: -2.61; 95% CI: -3.86, 0.09). From 2004 to 2009, a significant decline to 5.0 was observed (APC: -7.08; 95% CI: -9.28, -3.58). Subsequently, the rates stabilized by 2015 (3.8) (APC: -4.84; 95% CI: -6.58 to 2.04) but demonstrated a modest increase to 4.4 by 2020 (APC: 2.55; 95% CI: 0.08 to 8.19). Mortality rates were consistently higher among males (6.7 vs. 4.5 for females) and varied across racial/ethnic groups, with Non-Hispanic (NH) Whites (5.7) and NH Black/African Americans (5.4) exhibiting the highest rates, while Hispanics (2.8) and NH Asians/Pacific Islanders (2.3) had the lowest. Regional disparities showed that the Midwest had the highest AAMRs (6.5) followed by the Northeast (5.4), West (5.2), and South (4.8). Additionally, non-metropolitan areas exhibited significantly higher rates than metropolitan areas (7.1 vs. 5.0, respectively). The states in the 90th percentile for AAMRs were West Virginia, Mississippi, South Dakota, Nebraska, and North Dakota. Although there was an overall decline in mortality rates during the study period, disparities remained evident, with higher mortality observed among males, non-Hispanic Whites, residents of the Midwest, and individuals in non-metropolitan areas. This highlights the need for targeted public health intervention.

This cross-sectional descriptive study was conducted at the University of Health Sciences, Lahore, over 5 years (2016-2020) to explore the association of Panton-Valentine leucocidin (pvl) genes and staphylococcal cassette chromosome mec (SCCmec) types with hospital-acquired (HA) and community-acquired methicillin-resistant Staphylococcus aureus (MRSA). Panton-Valentine leucocidin genes in MRSA have been found in HA-MRSA strains, thereby raising the prevalence of highly virulent and resistant strains. Furthermore, the usage of staphylococcal cassette chromosome mec (SCCmec) typing is crucial for understanding the epidemiology and evolution of MRSA. The isolates of Staphylococcus aureus were acquired from clinical samples of the patients. Gram staining, catalase, coagulase, and DNAse tests were used for S. aureus confirmation. The methicillin resistance genes A and C (mecA and mecC) genes were detected to confirm MRSA by using a 30 µg cefoxitin disk. Panton-Valentine leucocidin gene identification and SCCmec typing (types I-V and XI) were conducted through polymerase chain reaction testing. Only 440 strains of MRSA were isolated, and 31.6% were positive for the pvl gene. The most prevalent SCCmec type among the MRSA isolates was type III, which was found in 42.7% of isolates. The pvl gene was detected in 74% of SCCmec types IV and V and in only 14% of SCCmec types I, II, III, and IIIA. This study revealed the dynamic adaptability of MRSA strains within healthcare settings, with the cooccurrence of the pvl gene and various SCCmec types highlighting the complexity of MRSA epidemiology. The urgent implementation of comprehensive strategies that integrate molecular surveillance and infection control measures is crucial for mitigating MRSA.

In this study, we evaluate the utility of ctDNA analysis in a large cohort of patients for whom ctDNA testing was ordered commercially with real-world application. Circulating tumor DNA (ctDNA) has emerged as a prognostic and predictive biomarker for assessing post-surgical molecular residual disease (MRD) and response to treatment. A real-world data analysis was performed using commercial ctDNA testing (SignateraTM) from patients (N=795, n=5,971 plasma samples) with stage I-III colon cancer treated at multiple US institutions. The association of ctDNA detection within the MRD window, during surveillance, and the impact of ACT was correlated with patient outcomes. ctDNA-positive patients during the MRD window and surveillance showed significantly shorter DFS compared to ctDNA-negative patients (hazard ratio (HR): 9.85, P<0.0001; HR: 26.91, P<0.0001). Multivariate analysis of the MRD window revealed ctDNA-positivity as the most significant factor associated with inferior DFS (adjHR: 7.7, P<0.001). MRD-positive patients who received ACT showed improved DFS compared to patients observed post-surgery (adjHR: 6.1, FDR adj P=0.0007). No ACT benefit was observed in MRD-negative patients (adj HR: 1.20, FDR adj P=0.768). On evaluating ctDNA dynamics from MRD to surveillance, patients who remained ctDNA-positive or converted from negative to positive showed a significantly inferior DFS (HR: 34.40, P<0.0001; HR: 13.65, P<0.0001) compared to persistently ctDNA-negative patients. Postsurgical ctDNA detection is prognostic of relapse and potentially predictive of ACT benefit in patients with resectable colon cancer, which may enable personalized surveillance, intervention, and/or trial options, ultimately improving patient outcomes.

Atrial fibrillation (AF) is the most prevalent cardiac arrhythmia, and if complicated by NSTEMI has a significant association with a higher all-cause and cardiovascular mortality. Previous studies show that patients with AF complicated by NSTEMI have a comparatively worse prognosis than AF patients without NSTEMI. In this study, we aimed to assess the trends and gender-based disparities in the incidence and in-hospital outcomes of AF complicated by NSTEMI in the U.S. adult population, using data from the Nationwide Inpatient Sample (NIS) dataset. The NIS database was searched from 2016 to 2022 to identify patients with ICD-10 Codes. Baseline demographic characteristics along with hospital-level variables were analyzed subsequently using the odds ratio. The demographic, clinical, and hospital-related characteristics of the study population were stratified by gender including 125,340 males and 88,554 females. The average age of patients was 75.14years, with males being younger (73.58years) compared to females (77.35years) (p<0.001). Overall, 10.8% of the patients died; females had a significantly higher mortality rate (11.3%) than males (10.5%) (p<0.001). The trends in age-adjusted mortality rate (AAMR) was 19996.9 per 100,000 hospitalizations in males who demonstrated higher AAMRs than females (18156.5). The mean length of hospital stay was consistently longer for the males compared to the females. The trend analysis for inflation-adjusted hospital costs demonstrated an upward trend in both males (p<0.001) and females (p<0.001). These findings underscore the importance of addressing gender-specific differences in the management of AF patients with NSTEMI to optimize patient resource allocation.

Esophageal cancer accounts for about 1% of all cancer diagnoses in the United States. An 82-year-old male presented to a dermatology clinic with a chief complaint of a skin lesion on the right lower lip. He denied any prior gastrointestinal symptoms or history. A shave biopsy of the lip lesion revealed adenocarcinoma. Subsequent positron emission tomography-computed tomography demonstrated findings concerning for esophageal malignancy with metastatic disease. Esophagogastroduodenoscopy identified a lesion in the distal esophagus, and biopsy confirmed invasive, moderately to poorly differentiated esophageal adenocarcinoma. The patient was referred to oncology, where he was diagnosed with stage IV metastatic esophageal adenocarcinoma. He was initiated on chemotherapy, which he tolerated well. This case highlights the rare presentation of stage IV esophageal adenocarcinoma as a solitary lip lesion without typical gastrointestinal symptoms. Given the rarity of lip involvement, clinicians should maintain a high index of suspicion for systemic malignancy in atypical skin lesions. Early biopsy and diagnosis are crucial for timely intervention and improved outcomes. The purpose of the study is to highlight the importance of maintaining a high index of suspicion for gastrointestinal malignancy, even in the absence of traditional gastrointestinal symptoms, when evaluating unusual skin lesions.

Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.